Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$72.06M+25.86%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven Roth
- Sector
- Real Estate
- Industry
- REIT - Retail
- Employees
- 103
- Beta
- 0.74
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.12
Financials
Revenue
$72.06M+25.9%Net Income
$27.40M+26.5%EBITDA
$47.31M+30.9%Free Cash Flow
$13.92M-70.3%EPS (diluted)
$5.33+26.0%Shares Outstanding (diluted)
5.14M+0.5%Operating Expenses
$1.99MCash & Debt
$299.79MReturn of Capital
$23.13MRevenue by Segment (annual)
$9.00MDividend per Share
$4.50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $213.18M | $28.22M | $5.50 |
| 2024 | $226.37M | $43.44M | $8.46 |
| 2023 | $224.96M | $102.41M | $19.97 |
| 2022 | $205.81M | $57.63M | $11.24 |
| 2021 | $206.15M | $132.93M | $25.94 |
| 2020 | $199.14M | $41.94M | $8.19 |
| 2019 | $226.35M | $21.17M | $4.14 |
| 2018 | $232.82M | $32.84M | $6.42 |
| 2017 | $230.57M | $80.51M | $15.74 |
| 2016 | $226.94M | $86.48M | $16.91 |
| 2015 | $207.91M | $76.91M | $15.04 |
| 2014 | $200.81M | $67.92M | $13.29 |
| 2013 | $196.46M | $56.91M | $11.14 |
| 2012 | $191.31M | $674.39M | $132.04 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ALX's reported EPS growth of -21.7% a year over 13 years. Historical EPS growth of -22% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $2.44
- Implied price
- $97.55
- Return from $232.24
- -15.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $48.50 — -79.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| -25.0% | -30.9% | -28.2% | -25.8% | -23.7% | -21.8% |
| -20.0% | -26.3% | -23.4% | -20.9% | -18.6% | -16.6% |
| -15.0% | -21.7% | -18.6% | -15.9% | -13.5% | -11.4% |
| -10.0% | -17.1% | -13.8% | -11.0% | -8.5% | -6.2% |
| -5.0% | -12.5% | -9.0% | -6.0% | -3.4% | -1.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (13)
- Newsglobenewswire.com·6d ago·Neutral
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026 Topline data from 120 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer expected in 2H 2027 SOUTH …
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Alexander's, Inc. (ALX) Q3 2026 Earnings Call Transcript Alexander's, Inc. (ALX) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
Alexander's Q3 Earnings Call Highlights Vornado Realty Trust reported higher third-quarter comparable funds from operations and continued leasing momentum across its New York office portfolio, as management pointed to rising rents, tightening availability of high-quality space and substantial signed revenue yet to commence.
View source ↗ - Newszacks.com·20d ago·Negative
Alexander's (ALX) Lags Q3 FFO and Revenue Estimates Alexander's (ALX) came out with quarterly funds from operations (FFO) of $7.07 per share, missing the Zacks Consensus Estimate of $8.2 per share. This compares to FFO of $2.91 per share a year ago.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Alexander's Announces Third Quarter Financial Results PARAMUS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2026 today and reported:
View source ↗ - Newsglobenewswire.com·25d ago·Negative
Alexander's Declares Quarterly $4.50 Dividend on Common Shares PARAMUS, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 20, 2026 to stockholders of record on November 9, 2026.
View source ↗ - Newsglobenewswire.com·34d ago·Negative
Alexander's Announces Third Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call PARAMUS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2026 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 2, 2026, before the New York Stock Exchange opens.
View source ↗ - Newsseekingalpha.com·46d ago·Negative
…ughly 40% chance of a cut within 12 months, making these REITs especially risky for income-focused investors. Nine REITs, including CLPR, BDN, CHCT, GOOD, NXRT, GNL, ALX, BRT, and AFCG, currently offer yields above 6.85% but have severe Dividend Safety concerns.
View source ↗ - Newsglobenewswire.com·55d ago·Positive
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
ALX Oncology to Present at Upcoming Investor Conferences in September SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
View source ↗ - Newszacks.com·103d ago·Positive
Best Momentum Stocks to Buy for August 11th DINO, QUAD and ALX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 11, 2026.
View source ↗ - Newszacks.com·103d ago·Positive
New Strong Buy Stocks for August 11th ALX, DINO, OPBK, CYD and HLLY have been added to the Zacks Rank #1 (Strong Buy) List on August 11, 2026.
View source ↗ - Newszacks.com·103d ago·Positive
Best Income Stocks to Buy for August 11th ALX, SHIP and QUAD made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 11, 2026.
View source ↗
Earnings
Mon, Feb 8(in 3 months)
Consensus estimate $2.94 per share
Typical surprise -15.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$5.33 vs $8.20miss
- Mon, Aug 3$3.02 vs $3.00beat
- Mon, May 4$2.60 vs $3.08miss
- Mon, Feb 9$2.43 vs $3.02miss
- Mon, Nov 3$2.91 vs $2.50beat
- Mon, Aug 4$1.19 vs $3.08miss
Estimates and results for ALX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALX officers and directors.
- Bought
- —
- Sold
- $2.3m
0 trades
7 trades
- Wight Russell B Jrsold
- Wight Russell B Jrsold
- Wight Russell B Jrsold
- Wight Russell B Jrsold
- Wight Russell B Jrsold
- Wight Russell B Jrsold
- Wight Russell B Jrsold
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
